Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

7.545
-0.905-10.71%
Volume:4.17M
Turnover:32.11M
Market Cap:7.94B
PE:-20.39
High:8.455
Open:8.455
Low:7.395
Close:8.450
52wk High:19.860
52wk Low:7.395
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:2.89
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-28.59%
ROA:-19.64%
PB:2.99
PE(LYR):-20.39
PS:7159.55

Loading ...

Ascletis Pharma proposes bylaw changes to allow hybrid shareholder meetings, e-voting

Reuters
·
Jun 02

Ascletis-B Maintains Stable Share Structure in May 2026; Public Float Confirmed Above 25%

Bulletin Express
·
Jun 01

ASCLETIS-B Shares Surge Over 5% in Early Trading as GIC Boosts Stake to 7% and U.S. Phase II Study Completes Enrollment

Stock News
·
May 21

GIC Private Limited Increases Stake in Ascletis-B (01672) by 122,000 Shares at HK$16.612 Each

Stock News
·
May 12

Citigroup: Fundamentals of China's Healthcare Sector Show Sustained Improvement, Top Picks Include WuXi AppTec (02359)

Stock News
·
May 11

HK Movers | Biotech Stocks Jump. InnoGen up over 44%; Clover Bio up over 11%; Junshi Bio up 9%; Laekna up 8%; Asymchem up over 3%; Tigermed up 2%

Tiger Newspress
·
May 11

ASCLETIS-B Adds 0.24 Million Shares from Option Exercises; Public Float Remains Compliant

Bulletin Express
·
May 07

Hong Kong Stock Announcement Highlights | TESSON HOLDINGS Subsidiary Signs MOU with DST to Establish JV for Hong Kong New Energy Charging and Battery Swap Network, First Phase to Build 10 Multi-Functional Stations

Stock News
·
May 06

ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)

Stock News
·
May 06

Ascletis to Showcase ASC47, ASC36 and ASC35 Obesity Therapies at ECO 2026; Combo Trial Shows 111.8% Higher Relative Weight Loss vs. Semaglutide Alone

Bulletin Express
·
May 06

Ascletis reports Phase I data for ASC47 obesity drug at ECO 2026

Reuters
·
May 06

ASCLETIS-B Shares Climb Over 3% in Morning Session on Upcoming ADA 2026 Conference Presentations

Stock News
·
Apr 30

ASCLETIS-B to Present Multiple Project Findings at ADA 2026 Scientific Sessions

Stock News
·
Apr 30

Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions

prnewswire
·
Apr 30

Ascletis reports 7.7% placebo-adjusted weight loss in ASC30 US Phase II study

Reuters
·
Apr 30

歌礼制药-B(01672)2025年业绩:营收达0.02028亿元,净亏损3.5988亿元,三大管线研发推进

Bulletin Express
·
Apr 29

HK Movers | Biotech Stocks Jump. Wuxi Apptec Soars 14% as 1Q Net Profit Rises 26.7%; Junshi Bio up 8%; Asymchem up Nearly 7%; Pharmaron up 4%

Tiger Newspress
·
Apr 28

Sagimet Biosciences Shares Rise With Focus on Acne Treatment

Dow Jones
·
Apr 27

ASCLETIS-B Completes Patient Enrollment for US Phase II Trial of Oral GLP-1R Agonist ASC30 in Diabetes

Stock News
·
Apr 27

Ascletis Completes Enrollment in U.S. Phase Ii Study of Asc30, an Oral Small Molecule Glp-1R Agonist, for the Treatment of Diabetes

THOMSON REUTERS
·
Apr 27